Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01MIP
|
|||
| Former ID |
DCL000292
|
|||
| Drug Name |
SU5614
|
|||
| Synonyms |
SU 5614; SU-5614; (3Z)-5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one; 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Airway inflammation [ICD-11: CA05; ICD-10: J00-J99; ICD-9: 460-519] | Terminated | [1] | |
| Company |
Sugen Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H13ClN2O
|
|||
| Canonical SMILES |
CC1=CC(=C(N1)C=C2C3=C(C=CC(=C3)Cl)NC2=O)C
|
|||
| InChI |
1S/C15H13ClN2O/c1-8-5-9(2)17-14(8)7-12-11-6-10(16)3-4-13(11)18-15(12)19/h3-7,17H,1-2H3,(H,18,19)/b12-7-
|
|||
| InChIKey |
XLBQNZICMYZIQT-GHXNOFRVSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:87159
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fms-like tyrosine kinase 3 (FLT-3) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Hematopoietic cell lineage | ||||
| Pathways in cancer | ||||
| Transcriptional misregulation in cancer | ||||
| Acute myeloid leukemia | ||||
| Central carbon metabolism in cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014776) | |||
| REF 2 | FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res. 2009 Apr 1;69(7):3032-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.